Blocking VEGF has anti-angiogenic effects and improves the delivery of anti-neoplastic therapies and T cell trafficking to the tumor (see Fig. 2 step 4 of cancer immunity cycle) [77]. This evidence concerns the gene VEGFA and neoplasm.